Obesity Strategic Roundup: Beyond GLP-1 Efficacy | Sep 1 – Oct 4 , 2026
How are next-generation obesity therapies reshaping competition in the GLP-1…
Nanexa–Novo Nordisk PharmaShell Deal: From Validation to Development | Lucid Diligence Brief
This Lucid Diligence Brief examines the Nanexa–Novo Nordisk PharmaShell deal…
Obesity Strategic Roundup | June 22–July 27, 2026
Obesity Strategic Roundup exploring Developments and Competitive Shifts…
Obesity Today—July 7, 2026
This week’s Obesity update highlights regulatory progress, portfolio expansion,…
Obesity Today—June 30, 2026
This week’s Obesity update highlights regulatory actions, clinical progress,…
Obesity Today—May 26, 2026
This week’s Obesity update highlights regulatory progress, late-stage clinical…
Obesity Today—May 19, 2026
This week’s Obesity update highlights regulatory oversight, advancing metabolic…
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…
Obesity Today—May 5, 2026
This week’s Obesity update highlights clinical progress, pipeline expansion,…
Endocrinology Today—April 28, 2026
This week’s Endocrinology update highlights regulatory actions, clinical…